Triamcinolone acetonide as a pharma grade API is processed into oral and parenteral dosage forms only after the particle size distribution, bulk density, crystalline phase, and residual solvent profile are matched to the specific unit operation. The compound is practically insoluble in water under USP solubility criteria, with aqueous solubility below 0.1 mg/mL; this property directly limits dissolution test design for tablets and capsules and requires micronized suspension technology for injectable products. Direct compression of 4 mg triamcinolone acetonide tablets is the shortest manufacturing route but imposes the narrowest particle-size and flow constraints, because the active component accounts for only 2.0% w/w of the final core weight. The micronized API, with particle size d90 ≤ 30 µm by laser diffraction per USP <429>, is first passed through a 600 µm stainless steel screen together with an approximately equal portion of lactose monohydrate in a low-humidity suite controlled at 25 ± 2°C and not more than 35% RH. The pre-blend is then charged to a V-blender at 60% nominal fill volume and rotated at 25 rpm for 15 min before the remaining lactose monohydrate or dicalcium phosphate anhydrous is added. The final blend composition for a 200 mg core is established at 2.0% w/w triamcinolone acetonide, 95.5% w/w spray-dried lactose monohydrate, 2.0% w/w croscarmellose sodium, and 0.5% w/w magnesium stearate; the magnesium stearate is introduced only in the final 3 min of blending to avoid hydrophobic film formation. Compression on a rotary tablet press fitted with 10 mm round flat-faced bevel-edge punches is run at 40 rpm and 10–14 kN main compression force, producing tablets with breaking force 60–80 N per USP <1217> and friability not more than 1.0% per USP <1216>. Content uniformity testing by USP <905> must provide an acceptance value not greater than 15; this is achieved only if the aggregate fines content below 75 µm in the final blend is controlled below 20% and the relative standard deviation of blend samples is below 3.0%. Dissolution is performed according to USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid containing 0.25% sodium lauryl sulfate, with a typical acceptance criterion of not less than 80% released in 30 min; published data for this specific configuration is limited, but the surfactant level is required to maintain sink conditions for the practically insoluble corticosteroid.

Will High-Shear Wet Granulation Control Triamcinolone Acetonide Segregation at 1 mg Dose?

For a 1 mg dose compressed into a 100 mg tablet core, the API represents only 1.0% w/w and blend segregation across transfer steps is a critical defect source. Wet granulation is selected only after direct compression and roller compaction are rejected because the API particle size d90 ≤ 30 µm and powder flow angle of repose exceed 45°, causing feeder bridging and weight variation on high-speed presses. A high-shear granulator with impeller speed 300 rpm and chopper speed 1,500 rpm is used to pre-blend triamcinolone acetonide with 50% of the lactose monohydrate mass for 5 min. The binder solution is 5.0% w/w povidone K30 in purified water, added by peristaltic pump at 1.0 L/min until granulation end point; end point is defined at a power consumption increase of 10–15% from the dry-mixing baseline. Intragranular crospovidone at 2.0% w/w is added near the end of wet massing to avoid over-hydration. The wet mass is passed through a 2.0 mm screen and dried in a fluid bed dryer with inlet air temperature 55°C and dew point not exceeding −20°C until granule loss on drying is 1.5–2.0% w/w by halogen moisture analyzer. Dry granules are milled through a 0.8 mm conical mill, yielding granules with d50 between 180–250 µm and fines below 20% below 75 µm. Extragranular crospovidone at 2.0% w/w, talc at 1.0% w/w, and magnesium stearate at 0.5% w/w are blended for 5 min. Compression on 8 mm tooling at 8–12 kN produces tablets with hardness 40–60 N, disintegration time below 10 min in water at 37°C per USP <701>, and friability below 1.0%. Residual granule moisture above 2.5% w/w causes picking and sticking during compression; below 1.0% w/w increases lamination risk at ejection. The terminal tablet is tested by USP <905> for content uniformity and USP <711> for dissolution in the same surfactant-containing acidic medium as the direct compression product.

Encapsulation of triamcinolone acetonide into size 3 hard gelatin capsules is preferred when the target dose is 2 mg and the patient population requires dose flexibility or avoidance of tablet compression stress. The total filled mass is 100 mg and the API occupies 2.0% w/w. The powder blend is prepared by geometric dilution of micronized API with lactose monohydrate 92.5% w/w, pregelatinized starch 5.0% w/w as disintegrant, colloidal silicon dioxide 0.5% w/w as glidant, and magnesium stearate 0.5% w/w. Blending is performed in a bin blender at 60% fill volume and 25 rpm for 20 min; over-lubrication must be avoided because the hydrophobic lubricant film retards dissolution of the practically insoluble API. Empty hard gelatin capsules are equilibrated at 25°C and 45% RH until shell moisture is 13–16% w/w; HPMC capsules require 4–6% w/w and are preferred in high-humidity export packaging because they do not undergo gelatin cross-linking at low relative humidity. A dosator-type capsule filling machine is set with a 10% powder compression ratio, and the process is run at 60,000 capsules/h with fill weight monitored every 30 min. Capsule weight variation is controlled by USP <905> with an acceptance value not greater than 15, and dissolution by USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.1 N hydrochloric acid with 0.25% sodium lauryl sulfate, with Q ≥ 80% at 30 min. Empty capsule defects such as body splitting and telescoping are observed below 12% shell moisture for gelatin and below 3% for HPMC; therefore seasonal packaging lines must maintain dew point controls and desiccant canisters for stability zone IVb shipments.

Roller-Compacted Ribbon Splitting in Low-Dose Triamcinolone Acetonide Granules

Dry granulation by roller compaction is evaluated when the triamcinolone acetonide dose is 4 mg and the formulation contains no water-sensitive components; the critical defect is ribbon splitting caused by uneven roll pressure or excessive fines generation. The pre-compaction blend contains 2.0% w/w triamcinolone acetonide, 50.0% w/w microcrystalline cellulose, 48.0% w/w lactose monohydrate, 3.0% w/w crospovidone intragranular, and 0.5% w/w magnesium stearate. A roller compactor with knurled rolls is operated at roll pressure 4–6 kN/cm, roll speed 5–10 rpm, and gap 2.0 mm; ribbon density is controlled at 1.2–1.4 g/cm³. Ribbons with density below 1.1 g/cm³ typically exhibit splitting and produce granule fines above 30%, whereas density above 1.5 g/cm³ reduces tablet porosity and slows disintegration beyond 15 min. Milling through a 1.0 mm screen generates granules with d50 350–500 µm and fines below 15% below 75 µm. Extragranular crospovidone at 2.0% w/w and magnesium stearate at 0.5% w/w are added before final blending. Compression on 12 mm tooling at 12–18 kN produces tablets with hardness 70–100 N, friability not more than 0.8%, and disintegration time below 15 min. Content uniformity is confirmed by USP <905>, and dissolution uses the same Apparatus 2 surfactant medium as other oral solids. Roller compaction is preferred over slugging when continuous manufacturing is used, because dwell time control across the ribbon width is more reproducible than single-station slug presses.

When Triamcinolone Acetonide Granules Are Reconstituted into a Pourable Oral Suspension

Reconstitution of dry granules to a 1 mg/mL oral suspension requires suspending agents that generate yield stress between 0.1 Pa and 0.5 Pa at 25°C, because the crystalline API has density about 1.4 g/cm³ and will sediment without shear-thinning structure. The dry granule formulation for a 5 mL dose contains 5 mg triamcinolone acetonide, 2.5 g sucrose or sorbitol as bulk sweetener, 10 mg xanthan gum, 15 mg sodium carboxymethylcellulose, 10 mg citric acid monohydrate, 15 mg sodium citrate dihydrate, 2 mg methylparaben, and 0.4 mg propylparaben. The sucrose is granulated in a high-shear granulator with a binder solution of the suspending agents; the wet mass is dried in a fluid bed at 50°C inlet air until loss on drying is below 1.0% w/w. The dried granules are milled through a 0.8 mm screen and blended with the preservative pre-blend and micronized API for 10 min in a tumble blender. The powder is filled into 60 mL amber PET bottles with desiccant canisters; the closure includes a tamper-evident cap and low-density polyethylene liner. Upon reconstitution with 50 mL purified water and shaking for 30 seconds, the suspension pH is 4.5–5.5, viscosity is 80–160 mPa·s at 25°C and 100 s⁻¹, and the API particle size d90 ≤ 50 µm avoids gritty mouthfeel. Multi-dose bottle deliverable volume is tested by USP <698>, and dose uniformity at the single-dose level is verified by USP <905> where unit-dose cups are used. The terminal product is stored in the reconstituted state for not more than 14 days at controlled room temperature, based on preservative effectiveness testing by USP <51> and stability under 21 CFR 211.166.

Terminal Moist-Heat Sterilization Is Not Feasible for Micronized Triamcinolone Acetonide Suspension

Aqueous triamcinolone acetonide suspension for intramuscular, intra-articular, and intralesional administration is compounded aseptic because terminal sterilization at 121°C for 15 min induces crystal aggregation, irreversible caking, and hydrolytic degradation of the C17-ester. The suspension contains 40 mg/mL triamcinolone acetonide, 0.75% w/v sodium carboxymethylcellulose as suspending vehicle, 0.04% w/v polysorbate 80 as wetting agent, 0.9% v/v benzyl alcohol as preservative, and 0.9% w/v sodium chloride for isotonicity, in water for injection q.s. The vehicle is prepared in ISO 14644-1 Grade C and sterilized by moist heat at 121°C for 15 min; the micronized API is rendered sterile by a validated dry heat or gamma irradiation cycle before aseptic addition in Grade A. Sterile filtration of the suspension is impossible because the 0.2 µm polyethersulfone membrane retains the micronized API; therefore the process follows EU GMP Annex 1 and ISO 13408-1 aseptic processing requirements. Vehicle pH is adjusted to 5.5–7.0 before API addition, and the suspension is homogenized under high shear until the API particle size is d90 ≤ 10 µm, d50 2–5 µm, with no particles above 25 µm when assessed by light obscuration per USP <788>. Viscosity after shaking is 20–60 mPa·s at 25°C and 50 s⁻¹, allowing withdrawal through a 21-gauge needle without clogging but preventing rapid sedimentation. Bacterial endotoxin is controlled by USP <85> with a limit based on maximum single dose, sterility by USP <71>, container closure integrity by USP <1207>, and osmolality by USP <785> at 270–330 mOsm/kg. The finished 5 mL multi-dose vial must be resuspended by shaking for at least 10 seconds before use; caking after storage at 2–8°C is a failure mode if the suspending agent concentration falls below 0.60% w/v or the API is overdried to residual moisture below 0.5% w/w.

Sterile lyophilized triamcinolone acetonide 40 mg per vial is manufactured when the suspension vehicle is incompatible with the patient population or when a single-dose, preservative-free parenteral product is required. The pre-lyophilization mixture is a sterile suspension containing 40 mg/mL triamcinolone acetonide, 50 mg/mL mannitol, and 20 mg/mL trehalose dihydrate in water for injection; the bulking solution is sterile filtered through a 0.2 µm membrane prior to aseptic addition of the micronized API. Freeze-drying cycle design requires freeze-dry microscopy to determine the collapse temperature of the mannitol-trehalose matrix; published data for this specific formulation is limited, but cycle development on a production freeze dryer with shelf mapping and Pirani versus capacitance manometer endpoint control is required. The suspension is filled into 10 mL Type I glass vials and lyophilized with freezing at −40°C for 4 h, primary drying at shelf temperature −20°C and chamber pressure 13.3 Pa for 24 h, and secondary drying at +25°C and 6.7 Pa for 6 h. Residual moisture by Karl Fischer per USP <921> Method 1c is not more than 1.5% w/w. The lyophilized cake must reconstitute with 1.0 mL of sterile water for injection within 60 seconds to form a uniform suspension with d90 ≤ 10 µm after shaking. Sterility is confirmed by USP <71>, bacterial endotoxin by USP <85>, particulate matter by USP <788>, and container closure integrity by USP <1207>. The single-dose terminal product is used for parenteral administration after reconstitution; residual solvents are controlled by USP <467> and elemental impurities by ICH Q3D.